Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY (2012) Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the general practice research database. BMJ Open 2(...
trials Rivaroxaban vs Apixaban and Major Ischemic or Hemorrhagic Events in Patients With AF JAMA Original Investigation December 21, 2021 This cohort study assesses major ischemic and hemorrhagic outcomes in Medicare beneficiaries with atrial fibrillation who were treated with rivaroxaban compared with ...
This cohort study assesses major ischemic and hemorrhagic outcomes in Medicare beneficiaries with atrial fibrillation who were treated with rivaroxaban
As with rivaroxaban, metabolism is dependent on CYP activity, with only 25% renal clearance.293 Clinical Experience. The ARISTOTLE trial randomly assigned 18,201 patients with AF and at least one other risk factor for stroke to receive either warfarin or apixaban 5 mg twice daily. The rate of...
However, in the ASTRO-APS trial, patients’ reported adherence to apixaban was 97.3%.19 The ongoing RISAPS (RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome; NCT03684564) trial is investigating the efficacy and safety of high-intensity rivaroxaban (15 mg twice daily) compared with ...
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-2394.PubMedGoogle ScholarCrossref 6. Go AS, Fang MC, Udaltsova N, et al; ATRIA Study Investigators...
Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting Article 18 September 2015 Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Str...
The PIONEER AF-PCI successfully treated patients with atrial fibrillation undergoing PCI with lower doses of rivaroxaban (2.5 mg twice daily) in combination with dual antiplatelet therapy15. The RE-DUAL PCI combined regular doses of dabigatran, adjusted per age and comorbidities, associated with a ...
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial Lancet Haematol (2016) K. Malec et al. The use of direct oral anticoagulants in 56 ...
The estimated odds ratio of stroke or systemic embolism was 1.35 for rivaroxaban vs dabigatran 150 mg (p=0.04), 0.97 for rivaroxaban versus dabigatran 110 mg (p=0.81), 1.22 for apixaban versus dabigatran 150 mg (p=0.18), 0.88 for apixaban versus dabigatran 110 mg (p=0.34) and 0.90 for ...